8-K: Fulcrum Therapeutics Inks $80 Million Deal with Sanofi for Ex-US Rights to Losmapimod, Bolstering Cash Runway

Fulcrum Therapeutics has entered into a collaboration with Sanofi, granting them exclusive rights to commercialize losmapimod outside the U.S. for an upfront payment of $80 million and potential milestones up to $975 million.

Summary

• Fulcrum Therapeutics has partnered with Sanofi, granting them exclusive rights to commercialize losmapimod outside the United States.
• Sanofi will make an upfront payment of $80 million to Fulcrum.
• Fulcrum is eligible to receive up to an additional $975 million in regulatory and sales-based milestones.
• Sanofi will pay Fulcrum tiered royalties ranging from low-teens to mid-twenties on annual net sales of losmapimod outside the U.S.
• Fulcrum will continue to conduct the ongoing Phase 3 clinical trial for losmapimod for FSHD.
• Global development costs will be shared equally between Fulcrum and Sanofi.
• Fulcrum will manufacture losmapimod for its activities and for Sanofi's clinical and commercial supply until Sanofi takes over manufacturing.
• Fulcrum's cash, cash equivalents, and marketable securities were $213.3 million as of March 31, 2024.
• Pro forma cash, including the $80 million upfront payment, is approximately $293.3 million.
• The company expects its cash to fund operations into 2027.
• Fulcrum reported a net loss of $26.9 million for the first quarter of 2024.
• Research and development expenses were $19.8 million for the first quarter of 2024.
• General and administrative expenses were $10.1 million for the first quarter of 2024.
• Topline data from the Phase 3 REACH trial for losmapimod is expected in the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document is largely positive due to the significant collaboration with Sanofi, the upfront payment, and the extended cash runway. The progress of the Phase 3 trial and the appointment of a new CMO also contribute to a positive outlook. However, the net loss and increased R&D expenses temper the sentiment slightly.

Positives

• The collaboration with Sanofi provides significant upfront capital and potential future revenue through milestones and royalties.
• The deal extends Fulcrum's cash runway into 2027, providing financial stability.
• The Phase 3 REACH trial is progressing, with topline data expected in the fourth quarter of 2024.
• The appointment of Patrick Horn as chief medical officer brings valuable experience to the company.
• The company has activated additional clinical trial sites for pociredir in sickle cell disease.
• The Phase 2 study for losmapimod, ReDUX4, demonstrated improvements in functional and structural outcomes.

Negatives

• The company reported a net loss of $26.9 million for the first quarter of 2024.
• Research and development expenses increased by $3.1 million compared to the same period last year.
• Collaboration revenue decreased by $0.3 million due to the completion of a previous agreement.
• The company's cash position decreased by $22.9 million from December 31, 2023 to March 31, 2024, before the Sanofi payment.

Risks

• The company's ability to achieve milestones and receive royalty payments is dependent on the success of losmapimod.
• Clinical trial results may not replicate positive findings from earlier studies.
• The company may face challenges in obtaining and maintaining regulatory approvals.
• The company may need to raise additional capital to achieve its business objectives.
• There are risks associated with managing executive and employee turnover, including integrating a new CMO.
• The company is subject to risks associated with advancing product candidates in clinical trials and initiating and enrolling clinical trials on the timeline expected.

Future Outlook

Fulcrum expects its current cash position, including the $80 million upfront payment from Sanofi, to fund operations into 2027. The company anticipates reporting topline data from the Phase 3 REACH trial in the fourth quarter of 2024 and is preparing for the potential NDA filing and commercial launch of losmapimod in the U.S.

Management Comments

• Alex C. Sapir, Fulcrum's president and chief executive officer, stated that it's a very exciting time for Fulcrum as they remain on track to report topline data for the Phase 3 REACH trial in the fourth quarter of 2024.
• Alex C. Sapir also mentioned that they are extremely pleased to announce a collaboration with Sanofi to leverage their global reach and rare disease expertise for the benefit of patients outside the U.S.
• The company highlighted the addition of Pat Horn as chief medical officer, who brings extensive late-stage rare disease development experience.

Industry Context

This announcement highlights the increasing trend of pharmaceutical companies collaborating to develop and commercialize treatments for rare diseases. Sanofi's expertise in rare diseases and global reach makes them a suitable partner for Fulcrum, allowing them to expand the potential market for losmapimod. The deal also reflects the high value placed on promising therapies for diseases with unmet medical needs, such as FSHD.

Comparison to Industry Standards

• The upfront payment of $80 million and potential milestones of $975 million are within the typical range for licensing deals of this nature in the biopharmaceutical industry, especially for a Phase 3 asset.
• The tiered royalty structure, ranging from low-teens to mid-twenties, is also standard for pharmaceutical licensing agreements.
• Companies like Sarepta Therapeutics and BioMarin Pharmaceutical have similar licensing agreements for rare disease therapies, often involving upfront payments, milestones, and royalties.
• The equal sharing of global development costs is a common practice in such collaborations, reflecting the shared risk and potential reward.
• Fulcrum's focus on genetically defined rare diseases aligns with the industry's increasing emphasis on precision medicine and targeted therapies.
• The Phase 3 REACH trial for losmapimod is a significant step towards potential regulatory approval, similar to other companies advancing late-stage clinical trials for rare diseases.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential future revenue from the Sanofi collaboration.
• Employees may experience increased job security and opportunities due to the company's improved financial position.
• Patients with FSHD may benefit from the potential availability of losmapimod outside the U.S.
• Patients with sickle cell disease may benefit from the continued development of pociredir.
• Sanofi will benefit from the exclusive rights to commercialize losmapimod outside the U.S.

Next Steps

• Fulcrum will continue to conduct the Phase 3 REACH trial for losmapimod.
• The company will prepare for the potential NDA filing and commercial launch of losmapimod in the U.S.
• Fulcrum will work with Sanofi on the global development plan.
• The company will continue to advance the Phase 1b trial of pociredir in sickle cell disease.
• Fulcrum will report topline data from the Phase 3 REACH trial in the fourth quarter of 2024.

Key Dates

Keywords

losmapimod, FSHD, Sanofi, collaboration, clinical trial, milestone payments, royalties, rare disease, pociredir, sickle cell disease, biopharmaceutical